EDSA - Edesa Biotech, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
4.2500
-0.2700 (-5.97%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close4.5200
Open4.3000
Bid4.1600 x 800
Ask4.5200 x 1300
Day's Range4.2500 - 4.4900
52 Week Range3.2800 - 17.4000
Volume8,336
Avg. Volume33,358
Market Cap32M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-5.7940
Earnings DateDec 16, 2019 - Dec 20, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
  • ACCESSWIRE

    Edesa Biotech Reports Financial Results for Short Period Fiscal Year

    TORONTO, ON / ACCESSWIRE / December 12, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the nine-month period ended September ...

  • ACCESSWIRE

    Edesa Biotech Reports Positive Healthy Volunteer Data and Expands Phase 2b Dermatitis Study to Patients with Facial Lesions

    TORONTO, ON / ACCESSWIRE / December 3, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported that the company's lead product candidate, EB01, has demonstrated positive safety data in healthy volunteers participating in its ongoing Phase 2b clinical study in chronic allergic contact dermatitis (ACD), a debilitating disease that is frequently caused by allergens present in the workplace. The healthy volunteer cohort at the outset of Edesa's study is designed to clear the way for using the experimental topical treatment on the face of ACD patients. Due to the high prevalence of symptoms on the face of ACD patients, the expansion of the study to facial symptoms is expected to address a key aspect of the disease, while broadening the potential patient population.

  • ACCESSWIRE

    Edesa Biotech Announces Upcoming Conference Schedule

    TORONTO, ON / ACCESSWIRE / November 5, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that its management will present at the H.C. Wainwright 5th Annual Israel Conference in Tel Aviv, Israel. Edesa completed a reverse acquisition with a Nasdaq listed company in June of this year and has since initiated a Phase 2b clinical study of its lead product candidate in allergic contact dermatitis.

  • ACCESSWIRE

    Edesa Biotech Enrolls First Patient in Phase 2b Dermatitis Study

    TORONTO, ON / ACCESSWIRE / October 21, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that the first patient has been enrolled in a Phase 2b clinical trial evaluating the company's lead product candidate, EB01, as a monotherapy for patients with moderate to severe chronic allergic contact dermatitis (ACD). The U.S. Food and Drug Administration recently approved Edesa's clinical protocol and provided a "safe to proceed" letter, which formally authorized the company to begin its clinical investigation. In the first cohort, ACD patients will be treated for 28 days with EB01 cream, an investigational medicine that contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor.

  • ACCESSWIRE

    Edesa Biotech to Present at H. C. Wainwright Global Investment Conference

    TORONTO, ON / ACCESSWIRE / August 29, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, will present at the H. C. Wainwright 21st Annual Global Investment Conference to be held September 8-10, 2019 in New York City. Edesa senior management will be available during the conference for one-on-one meetings. Members of the investment community who are interested in meeting with the company should contact conference coordinators to arrange an appointment or contact Edesa directly via email at investors@edesabiotech.com.

  • ACCESSWIRE

    Edesa Biotech Reports Quarterly Financial Results

    TORONTO, ON / ACCESSWIRE / August 14, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and six months ended June 30, ...

  • ACCESSWIRE

    Edesa Biotech Completes Manufacturing for Upcoming Dermatitis Study

    TORONTO, ON / ACCESSWIRE / July 25, 2019 / Edesa Biotech, Inc. (NASDAQ: EDSA), a clinical-stage biopharmaceutical company, reported today that the company has completed the manufacturing of its lead drug candidate EB01, a novel sPLA2 inhibitor that Edesa is developing as a potential treatment for chronic allergic contact dermatitis (ACD). Edesa is currently evaluating investigational centers in the U.S. and expects to proceed with enrolling the first patient into its Phase 2b clinical trial in the current quarter. “We have completed the manufacturing of our active pharmaceutical ingredient and have the drug product for the first cohort ready to distribute to our investigational centers in the U.S.,” said Michael Brooks , President of Edesa.

  • Edesa Biotech (EDSA) Stock Rockets Higher on Dermatitis Study Approval
    InvestorPlace

    Edesa Biotech (EDSA) Stock Rockets Higher on Dermatitis Study Approval

    Edesa Biotech (NASDAQ:EDSA) stock is flying higher on Thursday after getting approval from the U.S. Food and Drug Administration (FDA).Source: Shutterstock The approval from the FDA is for Edesa Biotech to move forward with a study of EB01. This is a novel sPLA2 inhibitor that the company is working on. It hopes to use it to treat chronic allergic contact dermatitis.According to Edesa Biotech, this approval will allow it to start a Phase 2b clinical protocol and clinical investigation into the drug. The company says that it is planning to enroll the first patient in the study starting sometime next quarter.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"There are limited options for ACD patients and we have been pleased with the level of interest from physicians in the U.S.," Dr. Par Nijhawan, CEO of Edesa Biotech, said in a statement. "The company is committed to rapidly advancing our clinical plans and remains on track to initiate our clinical study for EB01." * 6 Stocks Ready to Bounce on a Trade Deal Edesa Biotech says that it will be performing a randomized, double-blind, vehicle-controlled, sample size adaptive design study of the drug's ability to treat chronic allergic contact dermatitis. This will have patients using various EB01 creams with different strengths over a 28-day period. It also points out that the study may include up to 166 patients.EDSA stock was up 115% as of noon Thursday, but is down 26% since the start of the year. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Blue-Chip Stocks to Buy for a Noisy Market * 5 Strong Buy Biotech Stocks for the Second Half * 6 Stocks Ready to Bounce on a Trade Deal As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Edesa Biotech (EDSA) Stock Rockets Higher on Dermatitis Study Approval appeared first on InvestorPlace.

  • CNW Group

    Edesa Biotech Receives Approval to Proceed with U.S. Clinical Study

    TORONTO , June 20, 2019 /CNW/ -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, reported today that the U.S. Food and Drug Administration has notified the company that it may proceed with its clinical investigation of EB01, a novel sPLA2 inhibitor, which Edesa is developing as a potential treatment for chronic allergic contact dermatitis. The FDA "safe to proceed" letter formally approves the company's Phase 2b clinical protocol and authorizes the company to begin its clinical investigation.